After surveying 25 sleep specialists, Piper Jaffray analyst David Amsellem says his confidence is reinforced in Jazz Pharmaceuticals' treatment for excessive sleepiness associated with narcolepsy, JZP-110. The feedback "strongly suggests" that existing wakefulness promoting agents and stimulants are "inadequate in a significant chunk" of excessive daytime sleepiness patients, Amsellem tells investors in a research note. He believes the survey indicates "ample room for significant uptake" for JZP-110. The analyst reiterates an Overweight rating on Jazz with a $181 price target.